Literature DB >> 32476808

AGE-RAGE Stress in the Pathophysiology of Atrial Fibrillation and Its Treatment.

Kailash Prasad1.   

Abstract

Atrial fibrillation (AF) is the most common of cardiac arrhythmias. Mechanisms such as atrial structural remodeling and electrical remodeling have been implicated in the pathogenesis of AF. The data to date suggest that advanced glycation end products (AGEs) and its cell receptor RAGE (receptor for AGE) and soluble receptor (sRAGE) are involved in the pathogenesis of AF. This review focuses on the role of AGE-RAGE axis in the pathogenesis of AF. Interaction of AGE with RAGE generates reactive oxygen species, cytokines, and vascular cell adhesion molecules. sRAGE is a cytoprotective agent. The data show that serum levels of AGE and sRAGE, and expression of RAGE, are elevated in AF patients. Elevated levels of sRAGE did not protect the development of AF. This might be due to greater elevation of AGE than sRAGE. Measurement of AGE-RAGE stress (AGE/sRAGE) would be appropriate as compared with measurement of AGE or RAGE or sRAGE alone in AF patients. AGE and its interaction with RAGE can induce AF through alteration in cellular protein and extracellular matrix. AGE and its interaction with RAGE induce atrial structural and electrical remodeling. The treatment strategy should be directed toward reduction in AGE levels, suppression of RAGE expression, blocking of binding of AGE to RAGE, and elevation of sRAGE and antioxidants. In conclusion, AGE-RAGE axis is involved in the development of AF through atrial structural and electrical remodeling. The treatment modalities for AF should include lowering of AGE, suppression of RAGE, elevation of sRAGE, and use of antioxidants. © Thieme Medical Publishers.

Entities:  

Keywords:  advanced glycation end products; atrial electrical remodeling; atrial fibrillation; atrial structural remodeling; cell receptor for age; soluble RAGE; treatment modalities

Year:  2019        PMID: 32476808      PMCID: PMC7250637          DOI: 10.1055/s-0039-3400541

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  112 in total

Review 1.  Molecular basis of arterial stiffening: role of glycation - a mini-review.

Authors:  David R Sell; Vincent M Monnier
Journal:  Gerontology       Date:  2012-01-04       Impact factor: 5.140

Review 2.  Atrial remodeling and atrial fibrillation: mechanisms and implications.

Authors:  Stanley Nattel; Brett Burstein; Dobromir Dobrev
Journal:  Circ Arrhythm Electrophysiol       Date:  2008-04

3.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort.

Authors:  D Li; S Fareh; T K Leung; S Nattel
Journal:  Circulation       Date:  1999-07-06       Impact factor: 29.690

Review 4.  AGE-RAGE Stress, Stressors, and Antistressors in Health and Disease.

Authors:  Kailash Prasad; Manish Mishra
Journal:  Int J Angiol       Date:  2017-12-28

Review 5.  Atrial fibrillation pathophysiology: implications for management.

Authors:  Yu-ki Iwasaki; Kunihiro Nishida; Takeshi Kato; Stanley Nattel
Journal:  Circulation       Date:  2011-11-15       Impact factor: 29.690

6.  Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy.

Authors:  Y Y Li; Y Q Feng; T Kadokami; C F McTiernan; R Draviam; S C Watkins; A M Feldman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

7.  Prevalence of early-onset atrial fibrillation in congenital long QT syndrome.

Authors:  Jonathan N Johnson; David J Tester; James Perry; Benjamin A Salisbury; Carol R Reed; Michael J Ackerman
Journal:  Heart Rhythm       Date:  2008-02-08       Impact factor: 6.343

Review 8.  RAGE: a novel biological and genetic marker for vascular disease.

Authors:  Anastasia Z Kalea; Ann Marie Schmidt; Barry I Hudson
Journal:  Clin Sci (Lond)       Date:  2009-04       Impact factor: 6.124

9.  Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine.

Authors:  Stephen M Twigg; Zemin Cao; Sue V MCLennan; Wendy C Burns; Gail Brammar; Josephine M Forbes; Mark E Cooper
Journal:  Endocrinology       Date:  2002-12       Impact factor: 4.736

10.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study.

Authors:  A D Krahn; J Manfreda; R B Tate; F A Mathewson; T E Cuddy
Journal:  Am J Med       Date:  1995-05       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.